BR0015977A - métodos para tratar ou prevenir uma resposta inflamatória em um indivìduo, para tratar ou prevenir choque séptico em um indivìduo, para importar uma molécula biologicamente ativa para dentro de um núcleo de uma célula de um indivìduo, para tratar ou prevenir uma resposta inflamatória sistêmica em um indivìduo, e para inibir a importação de um fator de transcrição responsivo a estresse para dentro do núcleo de uma célula, e, complexo - Google Patents

métodos para tratar ou prevenir uma resposta inflamatória em um indivìduo, para tratar ou prevenir choque séptico em um indivìduo, para importar uma molécula biologicamente ativa para dentro de um núcleo de uma célula de um indivìduo, para tratar ou prevenir uma resposta inflamatória sistêmica em um indivìduo, e para inibir a importação de um fator de transcrição responsivo a estresse para dentro do núcleo de uma célula, e, complexo

Info

Publication number
BR0015977A
BR0015977A BRPI0015977-8A BR0015977A BR0015977A BR 0015977 A BR0015977 A BR 0015977A BR 0015977 A BR0015977 A BR 0015977A BR 0015977 A BR0015977 A BR 0015977A
Authority
BR
Brazil
Prior art keywords
individual
treating
preventing
inflammatory response
nucleus
Prior art date
Application number
BRPI0015977-8A
Other languages
English (en)
Inventor
Jack J Hawiger
Daniel Robinson
Ruth Ann Veach
Xue Yan Liu
Danya Liu
Sheila Timmons
Robert D Collins
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Publication of BR0015977A publication Critical patent/BR0015977A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"MéTODOS PARA TRATAR OU PREVENIR UMA RESPOSTA INFLAMATóRIA EM UM INDIVìDUO, PARA TRATAR OU PREVENIR CHOQUE SéPTICO EM UM INDIVìDUO, PARA IMPORTAR UMA MOLéCULA BIOLOGICAMENTE ATIVA PARA DENTRO DE UM NúCLEO DE UMA CéLULA DE UM INDIVìDUO, PARA TRATAR OU PREVENIR UMA RESPOSTA INFLAMATóRIA SISTêMICA EM UM INDIVìDUO, E PARA INIBIR A IMPORTAçãO DE UM FATOR DE TRANSCRIçãO RESPONSIVO A ESTRESSE PARA DENTRO DO NúCLEO DE UMA CéLULA, E, COMPLEXO". A presente invenção refere-se ao suprimento de moléculas biologicamente ativas, tais como peptídeos, dentro do interior de células, pela administração às células de um complexo compreendendo a molécula ligada a um peptídeo de sinal de importação competente. Tal suprimento pode ser utilizado, por exemplo, para tratar e/ou impedir condições inflamatórias, por exemplo mas não limitado a reações inflamatórias sistêmicas, tais como choque endotóxico, reações inflamatórias localizadas, tais como doenças e condições inflamatórias de pele e doenças inflamatórias tais como doenças autoimunes.
BRPI0015977-8A 1999-11-29 2000-11-29 métodos para tratar ou prevenir uma resposta inflamatória em um indivìduo, para tratar ou prevenir choque séptico em um indivìduo, para importar uma molécula biologicamente ativa para dentro de um núcleo de uma célula de um indivìduo, para tratar ou prevenir uma resposta inflamatória sistêmica em um indivìduo, e para inibir a importação de um fator de transcrição responsivo a estresse para dentro do núcleo de uma célula, e, complexo BR0015977A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/450,071 US6495518B1 (en) 1994-06-13 1999-11-29 Method for importing biologically active molecules into cells
PCT/US2000/032516 WO2001037821A1 (en) 1999-11-29 2000-11-29 Cell permeable peptides for inhibition of inflammatory reactions and methods of use

Publications (1)

Publication Number Publication Date
BR0015977A true BR0015977A (pt) 2006-06-06

Family

ID=23786649

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0015977-8A BR0015977A (pt) 1999-11-29 2000-11-29 métodos para tratar ou prevenir uma resposta inflamatória em um indivìduo, para tratar ou prevenir choque séptico em um indivìduo, para importar uma molécula biologicamente ativa para dentro de um núcleo de uma célula de um indivìduo, para tratar ou prevenir uma resposta inflamatória sistêmica em um indivìduo, e para inibir a importação de um fator de transcrição responsivo a estresse para dentro do núcleo de uma célula, e, complexo

Country Status (10)

Country Link
US (2) US6495518B1 (pt)
EP (1) EP1246616B1 (pt)
JP (1) JP2003514852A (pt)
KR (1) KR20030025901A (pt)
AT (1) ATE334664T1 (pt)
AU (1) AU783479B2 (pt)
BR (1) BR0015977A (pt)
CA (1) CA2391943A1 (pt)
DE (1) DE60029829T2 (pt)
WO (1) WO2001037821A1 (pt)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553929B2 (en) * 1994-06-13 2009-06-30 Vanderbilt University Cell permeable peptides for inhibition of inflammatory reactions and methods of use
US6495518B1 (en) * 1994-06-13 2002-12-17 Vanderbilt University Method for importing biologically active molecules into cells
CA2350882C (en) 1998-11-12 2011-02-22 Life Technologies Corporation Transfection reagents
US6773920B1 (en) 1999-03-31 2004-08-10 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
ATE385503T1 (de) 1999-06-28 2008-02-15 Inter K Pty Ltd Verfahren zur modulierung von integrin- vermittelter zellaktivitaet und hierfuer geeignete reagenzien
US20030104622A1 (en) * 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
US20040101488A1 (en) * 2000-03-24 2004-05-27 Balaram Ghosh Method for the prevention of septic shock lethality using curcumin
AUPR230500A0 (en) * 2000-12-22 2001-01-25 University Of Newcastle Research Associates Limited, The A method of modulating map kinase mediated cellular activity and agents useful in same
DE10148886A1 (de) * 2001-10-04 2003-04-30 Avontec Gmbh Inhibition von STAT-1
US20050181474A1 (en) * 2002-01-30 2005-08-18 Frank J. Giordano Transport peptides and uses therefor
GB0207624D0 (en) * 2002-04-02 2002-05-15 Cancer Res Ventures Ltd Chemokine and uses thereof
EP1684795A4 (en) 2003-10-17 2009-07-29 Inter K Pty Ltd METHODS AND AGENTS FOR THE TREATMENT OF CANCER
US8080251B2 (en) * 2004-07-21 2011-12-20 Centre For Dna Fingerprinting And Diagnostics Antigenic peptides
JP2008519839A (ja) * 2004-11-09 2008-06-12 セルテック バイオサイエンス エルエルシー 癌細胞におけるアポトーシスの増加のための組成物および方法
WO2008036060A2 (en) 2005-04-05 2008-03-27 Allergan, Inc. Clostridial toxin activity assays
US7517959B2 (en) * 2005-11-11 2009-04-14 Walter And Eliza Hall Institute Of Medical Research SOCS3 proteins
JP2009536670A (ja) * 2006-05-10 2009-10-15 スミスクライン・ビーチャム・コーポレイション 化合物の細胞浸透性を増加させるための組成物および方法
KR100887266B1 (ko) * 2007-09-04 2009-03-06 주식회사 프로셀제약 세포투과성 ｐ１８ 재조합 단백질, 이를 코딩하는폴리뉴클레오티드 및 이를 유효성분으로 함유하는 항암조성물
EP2185707B1 (en) * 2007-09-04 2013-07-03 Procell Therapeutics Inc. Cell permeable nm23 recombinant proteins, polynucleotides encoding the same, and anti-metastatic composition comprising the same
AU2008303928A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of NF-KAPPAB inhibitor SN50 and optionally angiotensin III as therapeutic agents in the treatment of EG HBV infection
US20110105408A1 (en) * 2008-02-22 2011-05-05 Inter-K Pty Limited Therapeutic peptides
MY155049A (en) 2008-03-14 2015-08-28 Allergan Inc Immuno-based botolinum toxin serotype a activity assay
EP2454276A4 (en) 2008-07-17 2013-07-10 Inter K Pty Ltd THERAPEUTIC AGENTS
JP5826635B2 (ja) 2009-03-13 2015-12-02 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 免疫系調節エンドペプチターゼ活性アッセイ
KR102017327B1 (ko) 2009-03-13 2019-09-03 알러간, 인코포레이티드 면역 기반 보툴리눔 독소 혈청형 ａ 활성 검정에 유용한 세포
KR101122845B1 (ko) * 2009-07-30 2012-03-21 부산대학교 산학협력단 경구용 염증성 장질환 치료제
US8835358B2 (en) 2009-12-15 2014-09-16 Cellular Research, Inc. Digital counting of individual molecules by stochastic attachment of diverse labels
EP2763688B1 (en) * 2011-10-06 2018-06-27 Vanderbilt University Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome
US8932559B2 (en) 2011-10-06 2015-01-13 Vanderbilt University Compositions and methods for preserving insulin-producing cells and insulin production and treating diabetes
US9388224B2 (en) * 2011-10-06 2016-07-12 Vanderbilt University Compositions for preserving insulin-producing cells and insulin production and treating diabetes
US10272133B2 (en) 2011-10-06 2019-04-30 Vanderbilt University Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome
EP3321378B1 (en) 2012-02-27 2021-11-10 Becton, Dickinson and Company Compositions for molecular counting
US9492544B2 (en) 2013-04-11 2016-11-15 Vanderbilt University Compositions and methods for targeting nuclear import shuttles and treating inflammatory disorders
US11571455B2 (en) 2013-04-11 2023-02-07 Vanderbilt University Methods and compositions for treating alcoholic liver disease
CN105705659B (zh) 2013-08-28 2019-11-29 贝克顿迪金森公司 大规模平行单细胞分析
US10195280B2 (en) 2014-07-15 2019-02-05 Life Technologies Corporation Compositions and methods for efficient delivery of molecules to cells
US10342847B2 (en) 2015-02-27 2019-07-09 Vanderbilt University Compositions and methods for preventing and reducing inflammation and treating disorders associated with inflammation
WO2016138496A1 (en) 2015-02-27 2016-09-01 Cellular Research, Inc. Spatially addressable molecular barcoding
CN107406888A (zh) 2015-03-30 2017-11-28 赛卢拉研究公司 用于组合条形编码的方法和组合物
WO2017044574A1 (en) 2015-09-11 2017-03-16 Cellular Research, Inc. Methods and compositions for nucleic acid library normalization
US10301677B2 (en) 2016-05-25 2019-05-28 Cellular Research, Inc. Normalization of nucleic acid libraries
US10640763B2 (en) 2016-05-31 2020-05-05 Cellular Research, Inc. Molecular indexing of internal sequences
US10202641B2 (en) 2016-05-31 2019-02-12 Cellular Research, Inc. Error correction in amplification of samples
IL265478B2 (en) 2016-09-26 2024-10-01 Becton Dickinson Co Measurement of protein expression using reagents with barcoded oligonucleotide sequences
US11319583B2 (en) 2017-02-01 2022-05-03 Becton, Dickinson And Company Selective amplification using blocking oligonucleotides
JP7536450B2 (ja) 2017-06-05 2024-08-20 ベクトン・ディキンソン・アンド・カンパニー 単一細胞用のサンプルインデックス付加
US11771739B2 (en) * 2017-06-16 2023-10-03 Vanderbilt University Methods and compositions for treating microbial inflammation
EP3788170B1 (en) 2018-05-03 2025-01-01 Becton, Dickinson and Company Molecular barcoding on opposite transcript ends
CA3097976A1 (en) 2018-05-03 2019-11-07 Becton, Dickinson And Company High throughput multiomics sample analysis
EP3849591A4 (en) * 2018-09-14 2022-10-12 Vanderbilt University METHODS AND COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES
EP3861134B1 (en) 2018-10-01 2024-09-04 Becton, Dickinson and Company Determining 5' transcript sequences
EP3877520B1 (en) 2018-11-08 2025-03-19 Becton, Dickson And Company Whole transcriptome analysis of single cells using random priming
EP3894552B1 (en) 2018-12-13 2026-01-28 Becton, Dickinson and Company Selective extension in single cell whole transcriptome analysis
EP3914728B1 (en) 2019-01-23 2023-04-05 Becton, Dickinson and Company Oligonucleotides associated with antibodies
CN113454234B (zh) 2019-02-14 2025-03-18 贝克顿迪金森公司 杂合体靶向和全转录物组扩增
WO2021016239A1 (en) 2019-07-22 2021-01-28 Becton, Dickinson And Company Single cell chromatin immunoprecipitation sequencing assay
EP4055160B1 (en) 2019-11-08 2024-04-10 Becton Dickinson and Company Using random priming to obtain full-length v(d)j information for immune repertoire sequencing
CN115244184A (zh) 2020-01-13 2022-10-25 贝克顿迪金森公司 用于定量蛋白和rna的方法和组合物
CN115279919A (zh) 2020-01-13 2022-11-01 贝克顿迪金森公司 使用含有du的寡核苷酸的细胞捕获
WO2021155057A1 (en) 2020-01-29 2021-08-05 Becton, Dickinson And Company Barcoded wells for spatial mapping of single cells through sequencing
US20230039219A1 (en) * 2020-02-18 2023-02-09 Cellivery Therapeutics, Inc. Improved Cell-Permeable Nuclear Import Inhibitor Synthetic Peptide for Inhibition of Cytokine Storm or Inflammatory Disease and Use Thereof
US12153043B2 (en) 2020-02-25 2024-11-26 Becton, Dickinson And Company Bi-specific probes to enable the use of single-cell samples as single color compensation control
WO2021231779A1 (en) 2020-05-14 2021-11-18 Becton, Dickinson And Company Primers for immune repertoire profiling
CN115803445A (zh) 2020-06-02 2023-03-14 贝克顿迪金森公司 用于5撇基因表达测定的寡核苷酸和珠
US11932901B2 (en) 2020-07-13 2024-03-19 Becton, Dickinson And Company Target enrichment using nucleic acid probes for scRNAseq
WO2022026909A1 (en) 2020-07-31 2022-02-03 Becton, Dickinson And Company Single cell assay for transposase-accessible chromatin
WO2022109343A1 (en) 2020-11-20 2022-05-27 Becton, Dickinson And Company Profiling of highly expressed and lowly expressed proteins
CN116685850A (zh) 2020-12-15 2023-09-01 贝克顿迪金森公司 单细胞分泌组分析
US20250302967A1 (en) * 2022-05-12 2025-10-02 Amytrx Therapeutics, Inc. Peptide formulations and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US5041376A (en) * 1988-12-09 1991-08-20 The Board Of Regents Of The University Of Texas System Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins
US5191063A (en) * 1989-05-02 1993-03-02 University Of Medicine And Dentistry Of New Jersey Production of biologically active polypeptides by treatment with an exogenous peptide sequence
US5126323A (en) * 1989-11-16 1992-06-30 Genetics Institute, Inc. Homogeneous purified k-fgf and compositions containing the same
US5811512A (en) * 1991-08-22 1998-09-22 The Trustees Of The University Of Pennsylvania Non-peptide peptidomimetics and related cyclic hexapeptides
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
US6495518B1 (en) 1994-06-13 2002-12-17 Vanderbilt University Method for importing biologically active molecules into cells
US5916872A (en) 1996-07-24 1999-06-29 Intrabiotics Pharmaceuticals, Inc. Cyclic peptides having broad spectrum antimicrobial activity
US5962415A (en) 1996-09-20 1999-10-05 Bristol-Myers Squibb Co. Compositions comprising a peptide inhibitor of nuclear protein translocation and an immunosuppressant and methods of use thereof
US5877282A (en) 1996-09-20 1999-03-02 Bristol-Myers Squibb Company Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof
US6323317B1 (en) 1996-11-01 2001-11-27 The Walter And Eliza Hall Institute Of Medical Research Therapeutic and diagnostics proteins comprising a SOCS box
CN1253565A (zh) 1996-11-01 2000-05-17 沃尔特及伊莱萨霍尔医学研究院 能调节对细胞因子的细胞反应性的治疗和诊断制剂
US6090539A (en) 1997-01-13 2000-07-18 Yale University Methods and compositions utilizing Rad51
WO1998034118A1 (en) 1997-01-30 1998-08-06 Yale University Diagnostic methods and compositions based on the distribution of rad51
JP2001508312A (ja) 1997-11-03 2001-06-26 インサイト・ファーマスーティカルズ・インコーポレイテッド サイトカインシグナリングのサプレッサ
US6248558B1 (en) 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
JP2003520577A (ja) 1999-10-21 2003-07-08 スミスクライン・ビーチャム・コーポレイション Ｅｐｏ一次応答遺伝子１、ｅｐｒｇ１
CA2417454A1 (en) * 2000-07-31 2002-02-07 Active Motif Peptide-mediated delivery of molecules into cells

Also Published As

Publication number Publication date
ATE334664T1 (de) 2006-08-15
US8324148B2 (en) 2012-12-04
AU783479B2 (en) 2005-11-03
EP1246616A1 (en) 2002-10-09
KR20030025901A (ko) 2003-03-29
AU1933101A (en) 2001-06-04
EP1246616B1 (en) 2006-08-02
US20040147435A1 (en) 2004-07-29
DE60029829D1 (de) 2006-09-14
EP1246616A4 (en) 2005-01-05
CA2391943A1 (en) 2001-05-31
DE60029829T2 (de) 2007-03-01
JP2003514852A (ja) 2003-04-22
WO2001037821A1 (en) 2001-05-31
US6495518B1 (en) 2002-12-17

Similar Documents

Publication Publication Date Title
DE60029829D1 (de) Zelldurchlässige peptide zur inhibierung von entzündungsreaktionen und deren verwendung
Weissleder et al. MR imaging and scintigraphy of gene expression through melanin induction.
Ding et al. Synthesis and characterization of peptide− cationic steroid antibiotic conjugates
ES2601827T3 (es) Agentes antagonistas de visfatina para el tratamiento del acné y de otras afecciones
WO1999040197A3 (en) Variants of the angiogenic factor vascular endothelial cell growth factor: vegf
BR0010648A (pt) Utilização de microesferas biodegradáveis que liberam um agente anticanceroso radiossensibilizador, processo de preparação de microesferas biodegradáveis, e, suspensão constituìda de uma solução estéril
WO2000014228A8 (en) Neutral amino acid transporter and gene thereof
DE69636937D1 (de) Durch trans-spaltung erhaltene therapeutische molekule
GR3021474T3 (en) Method of delivering molecules into eukaryotic cells
DE69834824D1 (de) Nukleinsäure, welche einen von lektin abstammenden faktor zur präservierung von progenitorzellen kodiert
BR0107917A (pt) Fonte para tecido de fìgado
Widgerow et al. Designing topical hyaluronic acid technology—Size does matter…
Namjoshi et al. Cyclic peptides as potential therapeutic agents for skin disorders
Peterson et al. Increased spectrin proteolysis in fibroblasts from aged and Alzheimer donors
WO1999007855A1 (de) Neutrale sphingomyelinase
AR020329A1 (es) UNA SUSTANCIA, EN PARTICULAR UNA RIBOZIMA, CAPAZ DE INHIBIR LA EXPRESION DE PRESENILINA 2, UNA MOLECULA DE DNA RECOMBINANTE QUE CODIFICA DICHA RIBOZIMA, UNVECTOR RECOMBINANTE QUE COMPRENDE EL cDNA CORRESPONDIENTE A DICHA RIBOZIMA, UNA CELULA HOSPEDADORA QUE COMPRENDE DICHO VECTOR RECOMBINANTE, UNA C
Jupe et al. Specialized chromatin structure domain boundary elements flanking a Drosophila heat shock gene locus are under torsional strain in vivo
Gozes et al. NAP accelerates the performance of normal rats in the water maze
AP2000001999A0 (en) Gene therapy method.
AU2256097A (en) A g protein-coupled receptor with an enlarged extracellular domain
Conte et al. Protective effects of thymosin β4 in a mouse model of lung fibrosis
ES2343672T3 (es) Nuevas proteinas transportadoras de aniones organicos.
EP1363658B1 (de) Beta-endorphin / crf - gentherapie zur lokalen schmerzbekämpfung
Adlerz et al. Down-regulation of amyloid precursor protein by peptide nucleic acid oligomer in cultured rat primary neurons and astrocytes
WO2005089252B1 (en) Methods and compositions for the treatment of obesity

Legal Events

Date Code Title Description
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1929 DE 26/12/2007.